A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk
Ruth Travis
(1)
,
Paul Appleby
(1)
,
Richard Martin
(2)
,
Jeff M.P. Holly
(3)
,
Demetrius Albanes
(4)
,
Amanda Black
(4)
,
H. Bas Bueno-De-Mesquita
(5)
,
June Chan
(6)
,
Chu Chen
(7)
,
María-Dolores Chirlaque
(8, 9)
,
Michael Cook
(4)
,
Mélanie Deschasaux
(10)
,
Jenny Donovan
(2)
,
Luigi Ferrucci
(11)
,
Pilar Galan
(10)
,
Graham G Giles
(12)
,
Edward Giovannucci
(13)
,
Marc Gunter
(14)
,
Laurel Habel
(15)
,
Freddie C. Hamdy
(16)
,
Kathy Helzlsouer
(17)
,
Serge Hercberg
(10)
,
Robert Hoover
(4)
,
Joseph A.M.J.L. Janssen
(18)
,
Rudolf Kaaks
(19)
,
Tatsuhiko Kubo
(20)
,
Loïc Le Marchand
(21)
,
E. Jeffrey Metter
(11)
,
Kazuya Mikami
(22)
,
Joan Morris
(23)
,
David Neal
(24)
,
Marian Neuhouser
(7)
,
Kotaro Ozasa
(25)
,
Domenico Palli
(26)
,
Elizabeth Platz
(27)
,
Michael Pollak
(28)
,
Alison Price
(1)
,
Monique J Roobol
(18)
,
Catherine Schaefer
(15)
,
Jeannette Schenk
(7, 29)
,
Gianluca Severi
(30, 31)
,
Meir J Stampfer
(13)
,
Pär Stattin
(32)
,
Akiko Tamakoshi
(33)
,
Catherine M Tangen
(7)
,
Mathilde Touvier
(10)
,
Nicholas Wald
(24)
,
Noel Weiss
(31)
,
Regina Ziegler
(4)
,
Timothy Key
(1)
,
Naomi E. Allen
(1)
1
Nuffield Department of Population Health [Oxford]
2 School of Social and Community Medicine [Bristol]
3 University of Bristol [Bristol]
4 NCI-NIH - National Cancer Institute [Bethesda]
5 RIVM - National Institute for Public Health and the Environment [Bilthoven]
6 UC San Francisco - University of California [San Francisco]
7 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
8 CIBERESP - Consorcio de Investigación Biomédica en Red especializado en Epidemiología y Salud Pública
9 Department of Epidemiology, Murcia Regional Health Council
10 CRESS - U1153 - Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle
11 NIA - National Institute on Aging [Bethesda, USA]
12 University of Melbourne
13 Harvard School of Public Health
14 Imperial College London
15 Kaiser Permanente
16 Nuffield - Nuffield
17 Mercy Medical Center
18 Erasmus MC - Erasmus University Medical Center [Rotterdam]
19 Division of Cancer Epidemiology
20 UEOH - University of Occupational and Environmental Health [Kitakyushu]
21 UHM - University of Hawai‘i [Mānoa]
22 Kyoto Prefectural University of Medicine [Kyoto, Japon]
23 QMUL - Queen Mary University of London
24 CAM - University of Cambridge [UK]
25 RERF - Radiation Effects Research Foundation [Hiroshima City, Japan]
26 Molecular and Nutritional Epidemiology Unit
27 Johns Hopkins Bloomberg School of Public Health [Baltimore]
28 Cancer Prevention Research Unit, Department of Oncology
29 University of Washington [Seattle]
30 Cancer Epidemiology Centre
31 Human Genetics Foundation (HuGeF)
32 Department of Surgical and Perioperative Sciences, Urology and Andrology
33 Hokkaido University Hospital [Sapporo]
2 School of Social and Community Medicine [Bristol]
3 University of Bristol [Bristol]
4 NCI-NIH - National Cancer Institute [Bethesda]
5 RIVM - National Institute for Public Health and the Environment [Bilthoven]
6 UC San Francisco - University of California [San Francisco]
7 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
8 CIBERESP - Consorcio de Investigación Biomédica en Red especializado en Epidemiología y Salud Pública
9 Department of Epidemiology, Murcia Regional Health Council
10 CRESS - U1153 - Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle
11 NIA - National Institute on Aging [Bethesda, USA]
12 University of Melbourne
13 Harvard School of Public Health
14 Imperial College London
15 Kaiser Permanente
16 Nuffield - Nuffield
17 Mercy Medical Center
18 Erasmus MC - Erasmus University Medical Center [Rotterdam]
19 Division of Cancer Epidemiology
20 UEOH - University of Occupational and Environmental Health [Kitakyushu]
21 UHM - University of Hawai‘i [Mānoa]
22 Kyoto Prefectural University of Medicine [Kyoto, Japon]
23 QMUL - Queen Mary University of London
24 CAM - University of Cambridge [UK]
25 RERF - Radiation Effects Research Foundation [Hiroshima City, Japan]
26 Molecular and Nutritional Epidemiology Unit
27 Johns Hopkins Bloomberg School of Public Health [Baltimore]
28 Cancer Prevention Research Unit, Department of Oncology
29 University of Washington [Seattle]
30 Cancer Epidemiology Centre
31 Human Genetics Foundation (HuGeF)
32 Department of Surgical and Perioperative Sciences, Urology and Andrology
33 Hokkaido University Hospital [Sapporo]
Mélanie Deschasaux
- Fonction : Auteur
- PersonId : 183648
- IdHAL : melanie-deschasaux
- ORCID : 0000-0002-3359-420X
- IdRef : 236007823
Pilar Galan
- Fonction : Auteur
- PersonId : 756893
- ORCID : 0000-0003-1706-3107
Serge Hercberg
- Fonction : Auteur
- PersonId : 1136672
- ORCID : 0000-0002-3168-1350
- IdRef : 02858709X
Gianluca Severi
- Fonction : Auteur
- PersonId : 775780
- IdHAL : gianluca-severi
- ORCID : 0000-0001-7157-419X
- IdRef : 198040598
Mathilde Touvier
- Fonction : Auteur
- PersonId : 1136541
Résumé
The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from 17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. After mutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development.
Origine : Fichiers produits par l'(les) auteur(s)